EdgarLookup

Semnur Pharmaceuticals, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Semnur Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q1 2025 Oct 2, 2024 $50.00M May 16, 2025
Q2 2025 Oct 2, 2024 $50.00M Aug 15, 2025
Q3 2024 Feb 22, 2024 $50.00M Nov 19, 2024
Q1 2024 Feb 22, 2024 $50.00M May 22, 2024
Q2 2024 Feb 22, 2024 $50.00M Aug 19, 2024

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($152.59M) Nov 12, 2025
Q3 2025 Jun 30, 2025 ($999.0K) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($385.1K) Aug 15, 2025
Q2 2025 Mar 31, 2025 ($194.6K) Aug 15, 2025
Q1 2025 Mar 31, 2025 ($194.6K) May 16, 2025
Q3 2025 Mar 31, 2025 ($665.0K) Nov 12, 2025
Q3 2025 Sep 30, 2024 ($1.30M) Nov 12, 2025
Q3 2025 Jun 30, 2024 ($1.11M) Nov 12, 2025
Q2 2025 Jun 30, 2024 $448.9K Aug 15, 2025
Q1 2025 Mar 31, 2024 $264.3K May 16, 2025
Q3 2025 Mar 31, 2024 ($1.51M) Nov 12, 2025
Q2 2025 Mar 31, 2024 $264.3K Aug 15, 2025
Q3 2024 Sep 30, 2023 $630.6K Nov 19, 2024
Q2 2024 Jun 30, 2023 $457.7K Aug 19, 2024
Q3 2024 Jun 30, 2023 $457.7K Nov 19, 2024
Q3 2024 Mar 31, 2023 ($1.01M) Nov 19, 2024
Q2 2024 Mar 31, 2023 ($1.01M) Aug 19, 2024
Q1 2024 Mar 31, 2023 ($1.01M) May 22, 2024
Q3 2023 Sep 30, 2022 $307.5K Nov 9, 2023
Q3 2023 Jun 30, 2022 ($30.8K) Nov 9, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($152.59M) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($374.9K) Aug 15, 2025
Q1 2025 Mar 31, 2025 ($246.6K) May 16, 2025
Q3 2025 Sep 30, 2024 ($1.30M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($168.2K) Aug 15, 2025
Q1 2025 Mar 31, 2024 ($368.3K) May 16, 2025
Q3 2024 Sep 30, 2023 ($505.9K) Nov 19, 2024
Q2 2024 Jun 30, 2023 ($563.7K) Aug 19, 2024